#United States #Healthcare Leadership #Northridge, California #Diabetes Technology #MiniMed

MiniMed's New Chapter: Board of Directors Announcement

MiniMed (Nasdaq: MMED), a leader in diabetes technology, has marked an important milestone by announcing its new Board of Directors. This announcement follows the company's separation from Medtronic, marking the beginning of its journey as an independent entity. The new board composition signifies MiniMed’s commitment to prioritizing growth, innovation, and improved accessibility to diabetes technology.

The Board's Focus

Chairman Kevin E. Lofton, who has a distinguished history in healthcare leadership, particularly emphasizes the need for a board that not only understands the intricacies of healthcare access but is also attuned to patient needs. The board is charged with guiding MiniMed on its mission to simplify diabetes management for patients around the globe. Lofton’s extensive experience within major health systems equips him to steer the company toward strategic growth and operational excellence.

Key Appointments

In conjunction with Lofton, several experienced figures have joined the board, including:

• - Que Dallara: Previously the EVP at Medtronic Diabetes, she took on the CEO role at MiniMed in March 2026, facilitating the company's transition to Nasdaq. Dallara's diverse experience in global leadership roles within healthcare and technology support her strategic oversight of the company.
• - Amy Bricker: As the Executive Vice President at Walgreens and a former president of Express Scripts, Bricker brings a wealth of operational expertise across community pharmacy and healthcare management to the table.
• - Glenn Eisenberg: A former executive from Labcorp, he is equipped with significant financial acumen and experience in managing large-scale mergers and acquisitions.

Strengthening Leadership and Operations

The diverse backgrounds of the board members suggest a multi-faceted approach to leadership, melding experience in healthcare access, technology, manufacturing, and corporate governance. This complement of skills is vital as MiniMed strives to innovate its product offerings and enhance patient engagement.

Vision for the Future

“Our mission is to reduce the burden of managing diabetes and make our integrated technologies more accessible and user-friendly,” said Dallara. With a board that exercises governance across various facets of the business, MiniMed is set to navigate the complexities of the healthcare landscape more adeptly. The goal is clear: to weave together insulin delivery and glucose sensing technologies with supportive human interactions, thus creating a streamlined and reliable experience for users.

MiniMed’s Legacy and Ongoing Mission

As a pioneer in diabetes care for over 40 years, MiniMed has been at the forefront of developing solutions that cater to the needs of individuals living with diabetes. With operations extending to 80 countries, their full-stack integrated system, which encompasses insulin delivery devices and continuous glucose monitors (CGMs), aims to revolutionize diabetes management worldwide. Their ongoing commitment is underlined by a focus on anticipating patient needs and reducing the complexities involved in daily diabetes management.

Conclusion

MiniMed's establishment as an independent entity comes with renewed vigor and a strategic focus on innovation within diabetes technology. As the company embarks on this new chapter with its experienced board, they remain dedicated to making every day a better day for individuals living with diabetes. This new era of leadership is set to drive forward the change and support that patients around the world need.